FHIT Suppresses Epithelial-Mesenchymal Transition (EMT) and Metastasis in Lung Cancer through Modulation of MicroRNAs

Metastasis is the principal cause of cancer death and occurs through multiple, complex processes that involve the concerted action of many genes. A number of studies have indicated that the Fragile Histidine Triad (FHIT) gene product, FHIT, functions as a tumor suppressor in a variety of common human cancers. Although there are suggestions of a role for FHIT loss in progression of various cancers, a role for such loss in metastasis has not been defined. Here, via in vivo and in vitro assays, we reveal that the enforced expression of FHIT significantly suppresses metastasis, accompanied by inhibition of the epithelial-mesenchymal transition (EMT), a process involved in metastasis through coordinate modulation of EMT-related genes. Specifically, miR-30c, a FHIT-upregulated microRNA, contributes to FHIT function in suppression of EMT and metastasis by directly targeting metastasis genes Metadherin (MTDH), High-mobility group AT—hook 2 (HMGA2), and the mesenchymal markers, Vimentin (VIM) and Fibronectin (FN1), in human lung cancer. Finally, we demonstrate that the expression pattern of FHIT and miR-30c is inversely correlated with that of MTDH and HMGA2 in normal tissue, non-metastatic and metastatic tumors, serving as a potential biomarker for metastasis in lung cancer.

[1]  C. Gilles,et al.  Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells , 2014, Molecular Cancer Research.

[2]  Charles M Perou,et al.  MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 , 2013, Nature Communications.

[3]  Samy Lamouille,et al.  TGF-&bgr; signaling and epithelial–mesenchymal transition in cancer progression , 2013, Current opinion in oncology.

[4]  R. Knight,et al.  MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets , 2012, Cell Death and Differentiation.

[5]  Junfeng Zhang,et al.  miR-30 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. , 2012, Biochemical and biophysical research communications.

[6]  A. Menssen,et al.  miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions , 2011, Cell cycle.

[7]  Shuxing Wang,et al.  Restoration of Fragile Histidine Triad (FHIT) Expression Inhibits Cell Growth and Induces Apoptosis in Cutaneous T-cell Lymphoma Cell Line , 2010, Cancer investigation.

[8]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[9]  F. Yu,et al.  Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells , 2010, Oncogene.

[10]  A. Laganà,et al.  Variability in the Incidence of miRNAs and Genes in Fragile Sites and the Role of Repeats and CpG Islands in the Distribution of Genetic Material , 2010, PloS one.

[11]  Guanghai Yang,et al.  MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). , 2010, Clinica chimica acta; international journal of clinical chemistry.

[12]  C. Gilles,et al.  Fhit regulates invasion of lung tumor cells , 2010, Oncogene.

[13]  Ryan D. Morin,et al.  Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. , 2009, Blood.

[14]  Dongquan Chen,et al.  Breast cancer metastasis suppressor 1 coordinately regulates metastasis‐associated microRNA expression , 2009, International journal of cancer.

[15]  M. Joglekar,et al.  The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells , 2009, Islets.

[16]  Raghu Kalluri,et al.  EMT: when epithelial cells decide to become mesenchymal-like cells. , 2009, The Journal of clinical investigation.

[17]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[18]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[19]  Michael Reiss,et al.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.

[20]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[21]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[22]  Krista A. Zanetti,et al.  Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.

[23]  G. Guler,et al.  Investigation of Mutations and Expression of the FHIT Gene in Turkish Patients with Brain Metastases Derived from Non-Small Cell Lung Cancer , 2007, Tumori.

[24]  Patricia Soteropoulos,et al.  MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. , 2007, Cancer research.

[25]  Anindya Dutta,et al.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. , 2007, Genes & development.

[26]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[27]  M. Lozano,et al.  Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer , 2004, Modern Pathology.

[28]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[29]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[30]  P. Zhao,et al.  [Loss of fragile histidine triad expression and metastasis in breast cancer]. , 2002, Ai zheng = Aizheng = Chinese journal of cancer.

[31]  C. Croce,et al.  FHIT gene therapy prevents tumor development in Fhit-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Croce,et al.  The FHIT gene at 3p14.2 is abnormal in breast carcinomas. , 1996, Cancer research.

[33]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[34]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[35]  L. Cope,et al.  HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma , 2009, Modern Pathology.

[36]  J. Zavadil,et al.  TGF-beta and epithelial-to-mesenchymal transitions. , 2005, Oncogene.